



## PulmoLife™

A COPD screening device reporting  
FEV1 & 'Lung Age'

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death worldwide according to the World Health Organisation and it is estimated that it will become the third leading cause of mortality by 2020.<sup>1</sup> COPD is often undiagnosed in its early stages, especially in smokers, who are most at risk and as a result not receiving treatment.

Since early detection and treatment of COPD can positively influence the disease course, it is important to screen those patients at risk. The PulmoLife™ (Cat. No. PL10) is the ideal tool to use as a quick check of lung function to highlight signs of disease as early as possible.

Simple and easy to use the PulmoLife™ offers a practical solution for COPD testing in adult smokers. A quick test using the PulmoLife™ measures and shows patients' FEV<sub>1</sub> and FEV<sub>1</sub>% predicted results<sup>2</sup> on its high visibility display. FEV<sub>1</sub> is strongly recommended as the measurement of choice in COPD screening and the percentage of the result against predicted values can be used to help determine the level of severity of disease.<sup>3</sup>

The PulmoLife™ then uses these results to calculate and display an optional 'Lung Age' estimation.<sup>4</sup> This is an equivalent 'Lung Age' based upon the FEV<sub>1</sub>% predicted results and can be used to show smokers the physical damage caused by smoking and encouraging smoking cessation.

Smokers are at the greatest risk of developing COPD and decline in lung function in susceptible smokers has been shown to be twice that of non-smokers.<sup>5</sup>

#### Suitable for

- FEV1 testing programmes
- Identification of early signs of COPD in smokers over 35
- Encouraging susceptible smokers to quit

#### References

1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990, and projected to 2020. Harvard University Press: Cambridge MA 1996
2. Stavem K, Aaser E, Sandvik L, Bjørnholt JV, Erikssen G, Thaulow E, Erikssen J. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J 2005; 25: 618-625
3. NICE COPD Guidelines 2004, Thorax 2004; 59 (suppl 1):1-232
4. Morris JF, Temple W. Spirometric 'Lung Age' estimation for motivating smoking cessation. Preventative Medicine, 1995; 14 655-662
5. Fletcher C, Peto R. BMJ 1977; 1: 1645-1648



## Features

- Measures and displays FEV<sub>1</sub> and FEV<sub>1</sub>% predicted
- 'Lung Age' Interpretation
- Quick and Easy to use
- Large graphical display
- Easy clean turbine
- Step-by-step screening instructions
- Robust storage pouch
- Customisable

## Specifications

### PulmoLife™

Transducer	Digital Volume Transducer
Resolution	0.01L
Accuracy	+/-3% To ATS/ERS Standardisation of Spirometry 2005
Volume Range	0 - 8 L As per ATS/ERS recommendations
Flow Range	0 - 14 L/s As per ATS/ERS recommendations
Predicted Values	1) ECCS 2) NHANES III 3) Asian (Chinese)
Display	Custom Liquid Crystal
Power Supply	3V Lithium Ion Coin Cell Battery
Dimension	131 x 59 x 38mm
Weight	Unit only: 96g Packed: 260g

International Sales:  
CareFusion Germany 234 GmbH,  
Leibnizstrasse 7,  
D-97204 Hoechberg,  
Germany.  
+49 (0) 931 4972 0 tel  
+49 (0) 931 4972 423 fax

U.K Sales:  
CareFusion UK 232 Ltd.  
The Crescent, Jays Close,  
Basingstoke,  
RG22 4BS, UK  
+44 (0) 1256 388550 tel  
+44 (0) 1256 330860 fax

Research and Design Office:  
CareFusion UK 232 Ltd.  
Quayside, Chatham Maritime,  
Chatham, Kent,  
ME4 4QY, UK  
+44 (0) 1634 899599 tel  
+44 (0) 1634 899598 fax



[carefusion.com/micromedical](http://carefusion.com/micromedical)

